Charles River Laboratories and Cure AP-4 today announced a manufacturing collaboration to provide High Quality (HQ) plasmid DNA for Cure AP-4’s Phase I/II gene therapy trials against Adapter-Protein 4 Hereditary Spastic Paraplegia (AP-4 HSP). The collaboration will leverage Charles River’s market leading expertise in plasmid DNA production at Alderley Park in Cheshire. Source: Charles River press release 6/9/2022